I

Incyte Corp
D

INCY

70.300
USD
-0.74
(-1.04%)
Market Open
Volume
82,960
EPS
2
Div Yield
-
P/E
171
Market Cap
13,535,789,338
OverviewSignalsIdeasNews
Related Instruments
    ABBV
    ABBV
    -4.630
    (-2.73%)
    172.35 USD
    AMGN
    AMGN
    -12.22
    (-4.13%)
    289.85 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    100.35 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    449.1 USD
    More
News

Title: Incyte Corp

Sector: Healthcare
Industry: Biotechnology
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.